Quick Dispatch:
Your tirzepatide for cardiovascular disease Full article: Tirzepatide for the Treatment of Heart Failure in Type 2 Diabetes Mellitus: (SUR)PASS, or Not? orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide for cardiovascular disease Full article: Tirzepatide for the Treatment of Heart Failure in Type 2 Diabetes Mellitus: (SUR)PASS, or Not? ships.
Need Help?
Questions about tirzepatide for cardiovascular disease Full article: Tirzepatide for the Treatment of Heart Failure in Type 2 Diabetes Mellitus: (SUR)PASS, or Not?, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide for cardiovascular disease Full article: Tirzepatide for the Treatment of Heart Failure in Type 2 Diabetes Mellitus: (SUR)PASS, or Not? in your area.
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
25.39
Tirzepatide and Cardiovascular Outcomes in Patients With Ventricular Tachycardia and Systolic Heart Failure
22.80
Mounjaro, Zepbound Lowers Risk of Cardiovascular Death by 62%
27.46
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
29.41
How Tirzepatide Supports Cardiovascular Health
23.26
Cardiovascular Outcomes with Tirzepatide Compared with Dulaglutide in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
20.62
In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx
23.38
